Abstract
This study aimed to evaluate the benefits and risks of patients with diffuse large B-cell lymphoma (DLBCL) treated with ibrutinib. PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched for relevant studies. The pooled overall response (OR), complete response (CR), and partial response (PR) were 57.9 %, 35.0 %, and 20.1 %, respectively. The pooled OR and CR of ibrutinib monotherapy were 41.6 % and 15.2 % and of ibrutinib + rituximab-based therapy were 72.0 % and 47.5 %, respectively. The relapsed/refractory DLBCL achieved a pooled OR and CR of 49.7 % and 27.7 %, respectively. The pooled OR and CR were 64.2 % and 56.9 % in non-germinal center B-cell-like (non-GCB) DLBCL and 68.3 % and 36.0 % in relapsed/refractory central nervous system lymphoma (CNSL), respectively. The pooled median progression-free and overall survival were 4.54 months and 11.5 months, respectively. 70.7 % and 52.6 % patients experienced ≥ grade 3 adverse events and serious adverse events. The ibrutinib-contained therapy was well tolerated and showed the potential to improve tumor response of patients with non-GCB DLBCL and relapsed/refractory CNSL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
